Bottom line
Is GNOM a good fund? The bottom line
GNOM is a managed technology sector ETF from Global X.
Annual fees run 0.5% — about $50 a year on every $10,000 invested, cheaper than 77% of technology sector funds we track.
It returned +19.0% over one year, −13.3% a year over five years (as of Dec 31, 2025, per its prospectus).
With $55.8 million in net assets and 51 holdings, its largest position is Guardant Health, Inc. (5.6%) and the top 10 make up 42.5% of the portfolio.
What stands out
- Low cost: cheaper than 77% of technology sector peers
What to watch
- 5-year return in the bottom quarter of its category
Updated Nov 19, 2026
What GNOM invests in
"The Global X Genomics & Biotechnology ETF (""Fund"") seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index (""Underlying Index"")."
"The Fund invests at least 80% of its total assets in the securities of the Solactive Genomics Index (""Underlying Index""). The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund may lend securities representing up to one-third of the value of the Funds total assets (including the value of the collateral received). The Underlying Index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science, as well as applications thereof (collectively, ""Genomics Companies""), as defined by Solactive AG, the provider of the Underlying Index (""Index Provider""). Genomics Companies may include companies in the biotechnology industry. Companies in the biotechnology industry include companies that are involved in business…
From the fund's prospectus (filed Mar 27, 2026).
GNOM performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| GNOM | +19.0% | −13.3% | — |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What GNOM costs
On a $10,000 investment, GNOM's 0.5% expense ratio costs about $50 a year. The prospectus estimates $628 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
GNOM top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Guardant Health, Inc. | 5.59% |
| 2 | Illumina, Inc. | 4.82% |
| 3 | Natera, Inc. | 4.15% |
| 4 | Biomarin Pharmaceutical Inc. | 4.09% |
| 5 | Arrowhead Pharmaceuticals, Inc. | 4.07% |
| 6 | Legend Biotech Corp | 4.05% |
| 7 | Praxis Precision Medicines Inc | 4.01% |
| 8 | Twist Bioscience Corp | 3.97% |
| 9 | Vertex Pharmaceuticals Incorporated | 3.95% |
| 10 | CRISPR Therapeutics AG | 3.85% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 42.5% of the fund. See all top 25 holdings and asset mix →